

# Laura Bojke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1399712/publications.pdf>

Version: 2024-02-01

61  
papers

1,885  
citations

361413

20  
h-index

265206

42  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2790  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reference Case Methods for Expert Elicitation in Health Care Decision Making. <i>Medical Decision Making</i> , 2022, 42, 182-193.	2.4	12
2	Digital interventions in mental health: evidence syntheses and economic modelling. <i>Health Technology Assessment</i> , 2022, 26, 1-182.	2.8	12
3	Does providing everyone with free-of-charge organised exercise opportunities work in public health?. <i>Health Policy</i> , 2022, 126, 129-142.	3.0	2
4	Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis. <i>Pharmacoeconomics - Open</i> , 2022, 6, 377-388.	1.8	4
5	Eliciting uncertainty for complex parameters in model-based economic evaluations: quantifying a temporal change in the treatment effect. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e21.	0.5	1
6	Modelling decay in effectiveness for evaluation of behaviour change interventions: a tutorial for public health economists. <i>European Journal of Health Economics</i> , 2022, 23, 1151-1157.	2.8	3
7	Cost-effectiveness of a proportionate universal offer of free exercise: Leeds Let's Get Active. <i>Journal of Public Health</i> , 2021, 43, 876-886.	1.8	4
8	Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 17-27.	2.1	15
9	Model to Determine the Cost-Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 266-274.	3.4	6
10	Delayed transfers of care for older people: a wider perspective. <i>Age and Ageing</i> , 2021, 50, 1073-1076.	1.6	4
11	Taking a local government perspective for economic evaluation of a population-level programme to promote exercise. <i>Health Policy</i> , 2021, 125, 651-657.	3.0	2
12	Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study. <i>Health Technology Assessment</i> , 2021, 25, 1-124.	2.8	29
13	The Cost Effectiveness of Ecotherapy as a Healthcare Intervention, Separating the Wood from the Trees. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11599.	2.6	10
14	Digital Interventions for Generalized Anxiety Disorder (GAD): Systematic Review and Network Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2021, 12, 726222.	2.6	10
15	Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 1-4.	2.1	5
16	The Relevant Perspective of Economic Evaluations Informing Local Decision Makers: An Exploration in Weight Loss Services. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 351-356.	2.1	6
17	Modelling the impact of physical activity on public health: A review and critique. <i>Health Policy</i> , 2020, 124, 1155-1164.	3.0	6
18	Estimating the health loss due to poor engagement with cardiac rehabilitation in Australia. <i>International Journal of Cardiology</i> , 2020, 317, 7-12.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of strategies preventing late-onset infection in preterm infants. Archives of Disease in Childhood, 2020, 105, 452-457.	1.9	5
20	Quantifying the impact of delayed delivery of cardiac rehabilitation on patients' health. European Journal of Preventive Cardiology, 2020, 27, 1775-1781.	1.8	8
21	Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT. Health Technology Assessment, 2020, 24, 1-190.	2.8	8
22	Improving cardiac rehabilitation uptake: Potential health gains by socioeconomic status. European Journal of Preventive Cardiology, 2019, 26, 1816-1823.	1.8	29
23	Understanding and addressing the challenges of conducting quantitative evaluation at a local level: a worked example of the available approaches. BMJ Open, 2019, 9, e029830.	1.9	1
24	Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease. PharmacoEconomics - Open, 2018, 2, 403-413.	1.8	7
25	Impact of specialist rehabilitation services on hospital length of stay and associated costs. European Journal of Health Economics, 2018, 19, 1027-1034.	2.8	8
26	Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments. International Journal of Environmental Research and Public Health, 2018, 15, 2459.	2.6	12
27	Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases – Time for a New Dialogue?. Journal of Rheumatology, 2018, 45, 1075-1077.	2.0	2
28	Model Structuring for Economic Evaluations of New Health Technologies. PharmacoEconomics, 2018, 36, 1309-1319.	3.3	13
29	Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses. Value in Health, 2018, 21, 715-723.	0.3	31
30	How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. PharmacoEconomics, 2017, 35, 767-776.	3.3	14
31	Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties. PharmacoEconomics, 2017, 35, 867-877.	3.3	22
32	Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. Genetic Testing and Molecular Biomarkers, 2017, 21, 705-716.	0.7	11
33	Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?. Clinical Rheumatology, 2017, 36, 1803-1810.	2.2	0
34	The cost-effectiveness of population Health Checks: have the NHS Health Checks been unfairly maligned?. Zeitschrift Fur Gesundheitswissenschaften, 2017, 25, 425-431.	1.6	11
35	Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-326.	2.8	21
36	Designing and Undertaking a Health Economics Study of Digital Health Interventions. American Journal of Preventive Medicine, 2016, 51, 852-860.	3.0	60

#	ARTICLE	IF	CITATIONS
37	A discrete choice experiment to explore patients'™ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2967-2974.	2.2	9
38	A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study. <i>BMJ Open</i> , 2016, 6, e010686.	1.9	12
39	The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 1101-1110.	3.3	2
40	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. <i>Value in Health</i> , 2016, 19, 885-891.	0.3	38
41	Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. <i>Value in Health</i> , 2015, 18, 865-875.	0.3	17
42	Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. <i>Rheumatology and Therapy</i> , 2015, 2, 113-125.	2.3	10
43	Belief Elicitation to Populate Health Economic Models of Medical Diagnostic Devices in Development. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 327-334.	2.1	16
44	Golimumab per il trattamento dell'™artrite psoriasica. <i>Pharmacoeconomics Italian Research Articles</i> , 2013, 15, 131-141.	0.2	0
45	Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse. <i>Medical Decision Making</i> , 2013, 33, 415-436.	2.4	32
46	Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. <i>Rheumatology</i> , 2012, 51, 210-215.	1.9	18
47	A Framework for Addressing Structural Uncertainty in Decision Models. <i>Medical Decision Making</i> , 2011, 31, 662-674.	2.4	72
48	Methods to elicit experts'™ beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration. <i>Statistics in Medicine</i> , 2011, 30, 2363-2380.	1.6	47
49	Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. <i>Rheumatology</i> , 2011, 50, iv39-iv47.	1.9	24
50	Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2011, 15, i-xxi, 1-329.	2.8	84
51	Golimumab for the treatment of psoriatic arthritis. <i>Health Technology Assessment</i> , 2011, 15, 87-96.	2.8	4
52	Eliciting Distributions to Populate Decision Analytic Models. <i>Value in Health</i> , 2010, 13, 557-564.	0.3	47
53	Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of Methods. <i>Value in Health</i> , 2009, 12, 739-749.	0.3	123
54	Linee guida di buona pratica per creare modelli analitico-decisionali nella valutazione delle tecnologie sanitarie. <i>Giornale Italiano Di Health Technology Assessment</i> , 2008, 1, 1-14.	0.1	0

#	ARTICLE	IF	CITATIONS
55	Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration. <i>Medical Decision Making</i> , 2008, 28, 33-43.	2.4	25
56	The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease – a UK collaborative study. The REFLUX trial. <i>Health Technology Assessment</i> , 2008, 12, 1-181, iii-iv.	2.8	319
57	A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 56	3.3	26
58	Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. <i>Health Technology Assessment</i> , 2007, 11, 1-226, iii.	2.8	64
59	Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2006, 24, 443-452.	3.3	5
60	Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment. <i>Pharmacoeconomics</i> , 2006, 24, 355-371.	3.3	390
61	Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2006, 10, 1-132. iii-iv.	2.8	97